Is the Options Market Predicting a Spike in HCA Healthcare Stock?
Investors need to pay close attention to HCA stock based on the movements in the options market lately.
HCA - HCA Healthcare, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$502.77
DETAILS
HIGH:
$635.00
LOW:
$413.00
MEDIAN:
$525.00
CONSENSUS:
$502.77
UPSIDE:
22.44%
Stock News
This HCA Healthcare Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top 50 High-Quality Dividend Growth Stocks For July 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable universe returned 8.69%, trailing SPY (10.10%) and SCHD (17.50%), but several individual stocks outperformed significantly. Currently, 39 out of 50 stocks offer a forward return estimate of at least 10%, with 22 appearing potentially undervalued by my free cash flow model.
HCA Healthcare's Fall Shouldn't Be Construed As Failing Health
HCA Healthcare remains a soft 'buy' despite recent underperformance, with fundamentals improving and shares attractively priced on an absolute basis. HCA's revenue and profitability continue to grow, driven by Medicare/Medicaid, increased equivalent admissions, and higher revenue per admission, even as the physical footprint shrinks. Management sustains shareholder returns through dividends and aggressive buybacks, with a 6.9% reduction in share count and $9.18 billion in remaining buyback capacity.
Your Hospital’s HR Won’t Tell You This: Nurses Can Legally Shield $49,000 a Year by Stacking a 403(b) and a 457(b)
Your hospital's benefits packet lists a 403(b), and it may also quietly list a 457(b) on a separate page. Human resources rarely explains what happens when a nurse funds both: the IRS treats them as separate buckets, not one aggregate limit. That is the loophole. For nurses employed by nonprofit hospitals, public health systems, or... Your Hospital's HR Won't Tell You This: Nurses Can Legally Shield $49,000 a Year by Stacking a 403(b) and a 457(b)
Can HCA's Capacity Expansion Strategy Fuel Its Long-Term Growth?
HCA is expanding hospitals, ERs and outpatient sites while investing billions in new capacity to support future healthcare demand and long-term growth.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Can HCA's Gene Therapy Milestone Drive Long-Term Growth?
HCA Healthcare highlights promising pediatric CRISPR gene therapy results as expanding specialty care and research investments support its long-term growth strategy.
HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. Sickle cell disease and beta thalassemia are inherited blood disorders that can cause serious, lifelong complications b.
HCA Healthcare (HCA) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Healthcare Added 35,200 Jobs—3 Stocks Positioned to Benefit
The May Jobs report told a familiar story for investors in healthcare stocks. The sector added 35,200 positions last month, led by ambulatory health services at 25,700 and hospitals at 6,000.
Is HCA Undervalued? DCF Says Worth $765
On June 10, 2026, we present a detailed DCF analysis for HCA Healthcare Inc (HCA), a company currently facing a challenging price performance context with a yea
Mission Bio and Human Cell Atlas Collaborate to Expand Access to Single-Cell Multiomics Ahead of HCA 2026 Meeting
SAN FRANCISCO--(BUSINESS WIRE)--Mission Bio, the leader in single-cell multiomics solutions, today announced a collaboration with the Human Cell Atlas (HCA), a global consortium working to create comprehensive reference maps of all human cells to advance the understanding, diagnosis, and treatment of disease. The announcement comes ahead of the upcoming Human Cell Atlas General Meeting 2026, taking place June 16–18 in Boston, where Mission Bio will participate alongside leading researchers and.
Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting
WALTHAM, Mass.--(BUSINESS WIRE)-- #HCA--Vizgen, Inc., a leader in spatial multiomics and developer of the MERSCOPE Ultra™ Platform, today announced it will debut a 3D Volumetric Tissue Mapping dataset in neurodegenerative brain tissue using MERFISH 2.0™ chemistry on the MERSCOPE Ultra Platform at the Human Cell Atlas (HCA) General Meeting, June 16-18, in Boston. The company will also launch Volumetric Tissue Mapping services and a new Cell Atlasing Hub, a central resource for the cell atlasing communi.
Top 50 High-Quality Dividend Growth Stocks For June 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.
3 Beaten-Down Stocks to Buy and Hold Forever
Don't wait too long to buy the dip on these stocks.
HCA Healthcare to Acquire CHCP to Strengthen Workforce Development
HCA plans to acquire CHCP, expanding healthcare education efforts and boosting its pipeline of trained professionals across hospitals and care sites.
HCA Healthcare Announces Agreement to Acquire The College of Health Care Professions
NASHVILLE, Tenn. & HOUSTON--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, and The College of Health Care Professions (CHCP), one of the largest allied healthcare training providers in Texas, today announced an agreement for HCA Healthcare to acquire ownership of CHCP. CHCP provides healthcare education to more than 8,000 students annually across 10 campuses throughout Texas and online. “The College of Health Care Professions has built a stro.
Price Targets
HCA Healthcare downgraded to Equal Weight from Overweight at Barclays
$427.00
(was $423.11)
Barclays
HCA Healthcare Inc (HCA) PT Lowered to $528 at Cantor Fitzgerald Amid Difficult Setup
$528.00
(was $424.80)
Sarah James
·
Raymond James
HCA Healthcare price target lowered to $525 from $588 at Cantor Fitzgerald
$525.00
(was $417.07)
Cantor Fitzgerald
HCA Healthcare Inc (HCA) PT Lowered to $413 at Bernstein SocGen Amid Policy Risks
$413.00
(was $367.69)
Truist Financial
HCA Healthcare price target lowered to $413 from $503 at Bernstein
$413.00
(was $363.23)
Bernstein
HCA Healthcare price target lowered to $530 from $560 at Stephens
$530.00
(was $444.76)
Stephens
HCA Healthcare price target lowered to $535 from $546 at Truist
$535.00
(was $432.46)
Truist Financial
HCA Healthcare price target lowered to $520 from $540 at Oppenheimer
$520.00
(was $432.46)
Oppenheimer
HCA Healthcare price target lowered to $534 from $593 at RBC Capital
$534.00
(was $432.46)
RBC Capital
HCA Healthcare price target lowered to $436 from $481 at Wells Fargo
$436.00
(was $432.46)
Wells Fargo
HCA Healthcare price target lowered to $510 from $550 at KeyBanc
$510.00
(was $432.46)
KeyBanc
HCA Healthcare price target lowered to $496 from $551 at Barclays
$496.00
(was $432.46)
Barclays
HCA Healthcare price target lowered to $525 from $590 at Jefferies
$525.00
(was $432.46)
Jefferies
HCA Healthcare price target raised to $635 from $598 at UBS
$635.00
(was $532.30)
UBS
HCA Healthcare price target raised to $541 from $503 at Bernstein
$541.00
(was $501.69)
Bernstein
HCA Healthcare price target raised to $540 from $520 at Mizuho
$540.00
(was $488.27)
Mizuho Securities
HCA Healthcare price target raised to $481 from $452 at Wells Fargo
$481.00
(was $482.53)
Wells Fargo
HCA Healthcare price target raised to $555 from $525 at RBC Capital
$555.00
(was $483.16)
RBC Capital
Bernstein Reiterates Market Perform Rating on HCA Healthcare Inc (HCA)
$503.00
(was $483.76)
KeyBanc
HCA Healthcare price target raised to $598 from $525 at UBS
$598.00
(was $487.53)
UBS